t(5;10)(q33;q21). 7 A common structural feature of TPM3 and H4/D10S170 proteins is the coiled-coil domain, which contributes with its dimerization/activation moiety to building tyrosine kinase fusion proteins.
Determination of specific chromosomal abnormalities plays an important role in the diagnosis, prognosis and management of hematological malignancies. Double minute chromosomes (dmins) are small chromatin bodies consisting of genes that are amplified in an extrachromosomal location. They are the genetic vehicles for amplifying oncogenes and drug-resistance genes. Such gene amplification events are frequently associated with tumor progression. Identification of dmins in hematologic malignancies has been reported primarily in acute myeloid leukemia. Recognized genes in the dmins include MYC oncogene and MLL transcription factor.
1,2 However, the occurrence of dmins is rare in lymphoid malignancies. Specific genetic material in the dmins and their clinical significance in the course of disease progression remains to be determined.
Using a multicolor fluorescence in situ hybridization (FISH) approach, we report here the identification and characterization of dmins in a patient with follicular lymphoma. Our patient is a 50-year-old female. She had a 3 ), but autologous stem cells could not be mobilized; nonetheless, the patient remained free of lymphoma for about 1 year thereafter. In February 2005, she again developed bilateral effusions and recurrent, bulky retroperitoneal lymphadenopathy. A pleural fluid specimen showed evidence of B-cell lymphoma with expression of CD19, CD20 and monotypic lambda on the malignant lymphocytes. A bone marrow biopsy showed 20-30% involvement with a mixture of small and large malignant lymphocytes. The patient was treated with REPOCH chemotherapy and involved field radiation, responded and has been maintained on rituximab every 2 weeks while awaiting identification of a matched unrelated donor.
At the time of relapse in February 2005, a bone marrow specimen as well as a pleural fluid specimen was submitted for cytogenetic evaluation. A t(14;18) translocation and 1-3 dmins were found in all of the analyzed metaphase cells from the pleural fluid. The karyotype designation was 46,XX, t(14;18)(q32;q21),1-3dmin [20] . The same abnormalities were also seen in five of the 20 cells (25%) from the bone marrow. FISH analysis was performed using an IGH/BCL2 probe set (Abbott Molecular, Des Plaines, IL, USA) to confirm that the t(14;18) translocation resulted in an IGH/BCL2 fusion (Figure 1a ). This probe set not only detected an IGH/BCL2 fusion but also revealed a submicroscopic interstitial deletion of the telomeric end of the IGH gene. Such interstitial deletion adjacent to the t(14;18) translocation is not uncommon in follicular lymphoma. 3 The occurrence of dmins is a rare event in lymphoid malignancies. In order to identify the origin of dmins in this case, we used a multicolor (24-color chromosome painting) FISH probe set (Abbott Molecular, Des Plaines, IL, USA) to analyze the cells with dmins. In this analysis, each chromosome pair was painted with a specific color. As the dmins displayed the same color as chromosome 2, we concluded that they were derived from chromosome 2 (Figure 1b) . Considering that follicular lymphoma sometimes transforms into a more aggres- sive diffuse large B-cell lymphoma and that amplification of oncogene REL (maps to chromosome 2p16) has been found in a high percentage of human B-cell lymphoma, 4 we attempted to determine whether the dmins in our patient contain the REL gene.
We searched the National Center for Biotechnology Information (NCBI) database and identified a bacteria-derived artificial chromosome (BAC) clone RP11-373L24 (BACPAC Resources, Oakland, CA, USA) that contains the REL gene. Isolated DNA from this clone was labeled with fluorochromes following the protocol described in our previous studies 5 and validated as a FISH probe on normal controls. This probe was then used to characterize dmins in our patient. Positive hybridization signals were observed on the dmins (Figure 1c) , demonstrating the presence of the REL gene in the dmins. In order to address whether the REL amplification was present in the initial lymph node biopsy, we performed retrospective FISH analysis with the same probe on paraffin-embedded tissue. No REL amplification was evident (Figure 1d ). In addition, we used Ki-67/MIB-1 immunoperoxidase stain 6 to compare the mitotic index in the initial lymph node biopsy and in the relapsed bone marrow. No significant changes were observed.
In this report, we demonstrated REL amplification in the form of dmins in a patient with follicular lymphoma. To our knowledge, this is the first report of direct demonstration of REL-positive dmins in lymphoma. Interestingly, no REL amplification was detected in the initial lymph node biopsy and the REL-positive dmins appeared to be the sole detectable secondary aberration at the time of relapse. REL encodes a nuclear factor-kB transcription factor. It is amplified or mutated in several cases of human B-cell lymphoma and can transform chicken lymphoid cells in vitro. REL regulates the expression of numerous cellular genes including genes involved in lymphoid cell development and proliferation. 4 REL may also cooperate with other genes in B-cell tumorigenesis. One of the cooperating candidates is BCL11A, which is located near REL and is frequently coamplified with REL in B-cell lymphomas. 7 Owing to the limited amount of available specimen, we were not able to determine the boundary of the dmin in our patient. However, we believe BCL11A is likely to be present in the dmins. This is because the estimated size of the dmin in this case is greater than 5000 kb and the distance between REL and BCL11A is about 300 kb. BCL11A encodes a zinc-finger Kruppel-like transcription repressor protein, but its target genes remain to be revealed.
Although REL gene amplification has been reported in 15-20% of large B-cell lymphoma and 15-20% of follicular B-cell lymphoma, 4 it is unclear if such amplifications play a key role in oncogenesis. Based on the finding that there was no clear correlation between REL amplification and its nuclear accumulation, Houldsworth et al. 8 suggested that REL amplification may not lead to abnormal REL activation. However, others have proposed that REL amplification may be important at an earlier growth stage. 4 In a recent study, Trautmann et al. In a small percentage of patients with acute leukemia, conversion of cell lineage can occur at relapse. 1 Such conversion of cell lineage usually concerns a switch from precursor-B-acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML) and is most frequently assumed to represent a therapy-related secondary malignancy. 2 However, true lineage switches of clonally related leukemic cells have
